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DOSING OF BENZODIAZEPINE HYPNOTICS IN 
ELDERLY PATIENTS
Young JK, Schultz D, Foster D, Heller S
Solucient, Ann Arbor, MI, USA
OBJECTIVES: Use of benzodiazepines in elderly patients
has been associated with adverse outcomes including mo-
tor vehicle accidents and hip fractures from falls. Evi-
dence exists showing greater risk of adverse outcomes
with higher doses of these drugs regardless of drug half-
life. Initial administration of lower doses to elderly and
debilitated patients is generally recommended for benzo-
diazepine hypnotics. We analyzed whether these recom-
mendations are generally followed when prescribing
these drugs to inpatients. METHODS: Demographic and
hospital information for all patients receiving fluraze-
pam, triazolam, or temazepam between January 1998
and June 2000 was extracted from Solucient’s Projected
Inpatient International Classification of Clinical Services
(pICCS) database. This database contains demographic,
hospital, clinical, and detailed service level information
for inpatients from over 150 short-term, non-federal, US
hospitals. The percent of elderly patients (over age 65) re-
ceiving the recommended dose was determined. The rela-
tionship of patient age, hospital teaching status, bed size,
and geographic region on the likelihood of following dos-
ing recommendations was analyzed. RESULTS: We ex-
tracted information for 14,929 inpatients receiving flu-
razepam, 8,147 inpatients receiving triazolam, and 125,625
patients receiving temazepam. Among elderly patients re-
ceiving one of these drugs, 72.1% of patients receiving
flurazepam, 49.8% of patients receiving temazepam, and
7.1% of patients receiving triazolam received the recom-
mended dose. For all three drugs, patient age was directly
correlated with the likelihood of receiving the recom-
mended dose. There was no consistent relationship be-
tween teaching status, hospital bed size, or geographic re-
gion and the likelihood of receiving the recommended
dose, although teaching hospitals were much more likely
than non-teaching hospitals to provide the recommended
dose for temazepam and triazolam (OR 5.3 CI 4.9–5.8
for temazepam; OR 2.7 CI 2.2–3.2 for triazolam). CON-
CLUSIONS: Many elderly inpatients are prescribed higher
than recommended doses of hypnotic benzodiazepines,
suggesting need for systemic interventions to avert ad-
verse outcomes.
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PHARMACOTHERAPIES
Lenert LA, Minh C, Jackson C
University of California–San Diego, San Diego, CA, USA
BACKGROUND: There are a wide range of therapeutic
options for migraine headaches that have different costs
and benefits, and little is known about the cost-effective-
ness of specific therapies. OBJECTIVE: Assess patients’
preferences for outcomes of treatment of migraine head-
ache based on their marginal willingness to pay (WTP)
for treatment attributes. METHODS: In an Internet-
based study, we used computer software to measure im-
portance ratings of attributes of pharmacological mi-
graine therapies, then elicited their WTP for an ideal drug
(one that was 100% effective, worked quickly, and had
no adverse effects) and for “less than ideal” drugs with
relatively poor performance in one specific attribute of
performance. Patients: 429 self-identified migraineurs re-
cruited via an Internet web site. RESULTS: A high pro-
portion of patients in the study had symptoms consistent
with migraine etiology of headache (91% in enrollees,
99% of patients providing WTP ratings). Expert review
confirmed a large proportion of symptom profiles as be-
ing consistent with migraine (90% of the first 109 enroll-
ees). Median WTP for an ideal migraine therapy was
4.1% of estimated monthly income or $130 (US), and
was associated with severity of pain, frequency of head-
aches, and the types of medications used in the past.
WTP was reduced when pharmaceuticals offered less
benefit (median reductions of a $75 per month for 50%
chance of causing a rebound headache; $62 for rendering
user unable to work, $50 for a two-hour delay in effect;
and $15 for failure to relieve nausea). Reductions in WTP
were largely consistent with importance ratings for at-
tributes except for “speed of relief,” which was more
highly valued. CONCLUSIONS: Elicitation of patients’
WTP for specific attributes of a therapy appears to be a
feasible method to quantify patients’ preferences for out-
comes. Further work is needed to compare this approach
to traditional methods for measurement of WTP.
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USE OF GALANTAMINE IN THE NETHERLANDS 
FOR THE TREATMENT OF MILD TO MODERATE 
ALZHEIMER’S DISEASE
Caro J1, Salas M1, Getsios D1, Mehnert A2, for the AHEAD 
Study Group
1Caro Research Institute, Concord, MA, USA; 2Janssen 
Research Foundation, Beerse, Belgium
OBJECTIVES: To estimate the costs and long-term
health effects of using galantamine in Dutch patients with
mild to moderate Alzheimer’s disease (AD). METHODS:
A pharmacoeconomic model was developed. It consists
of two components: an initial module based on two gal-
antamine clinical trials and a subsequent module that
uses trial results and equations derived from recently
published data to forecast the time until patients require
full time care (FTC) or die. The analyses compare treat-
ment with galantamine 24 mg to no pharmacologic treat-
ment. Cost estimates were based on resource use profiles
of patients with AD in the Netherlands and are reported
in 1998 guilders (NLG) determined from the perspective
of a comprehensive care payer. Future costs are dis-
